WEST PALM BEACH, Fla.--(BUSINESS WIRE)-- RiverNorth Opportunities Fund, Inc., RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. and RiverNorth Capital and Income Fund, Inc. are each pleased to announce the declaration of preferred dividends for the second quarter of 2024, as detailed below. Ex Date Record Date Payable Date May 1, 2024 May 2, 2024 May 15, 2024 Fund Name Preferred Stock Series NYSE Distribution Per Share RiverNorth Opportunities Fund, Inc. 6.000% Series A Perpetual Prefe...
DENVER--(BUSINESS WIRE)-- (NYSE: NEM, TSX: NGT, ASX: NEM, PNGX: NEM) a annoncé aujourd'hui la nomination de au poste de directeur de la technologie. François rejoindra l'équipe de direction de Newmont et dirigera les travaux techniques dans l'ensemble de l'entreprise afin d'améliorer les performances opérationnelles et de stimuler la croissance. Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : Newmont Appoints Mining Industry Veteran Francois Hardy as Chief Technology Officer (Photo: Business Wire) François prendra la relève de, , CTO par intérim, ...
Moody's Ratings (Moody's) has assigned a Aa3 rating to Miami-Dade County, FL's $319 million Water and Sewer System Revenue Bonds, Series 2024A and $147 million Water and Sewer System Revenue Refunding Bonds, Series 2024B. Concurrently, Moody's Ratings has affirmed the Aa3 and A1 ratings on senior an...
Comstock to Host 1Q24 Earnings Call on April 30, 2024 VIRGINIA CITY, Nev., April 19, 2024 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE: LODE) (“Comstock” or the “Company”) is pleased to announce that its Executive Chairman, Director & CEO, Corrado De Gasperis, and its COO, William McCarthy, will be presenting an overview of the Company’s 1Q24 financial results, upcoming milestones, and how the Comstock’s systemic platform is optimizing results on Tuesday, April 30, 2024, via a webinar. Investors and all other interested parties are invited to register below. Date: April 30, 2024Time: 8:00 am...
Moody's Ratings ("Moody's") has today affirmed the Baa3 local and foreign currency long-term issuer ratings of the City of Budapest and maintained the stable outlook. At the same time, Moody's has affirmed Budapest's Baseline Credit Assessment (BCA) of baa3. RATINGS RATIONALE RATIONALE FOR THE R...
Moody's Ratings (Moody's) has today placed all ratings and assessments of Coventry Building Society ("Coventry BS") on review for downgrade, with the exception of the Society's Prime-1 short-term Counterparty Risk Rating (CRR) and short-term Prime-1(cr) Counterparty Risk (CR) Assessment which have b...
Moody's Ratings (Moody's) has today affirmed the Government of Lithuania's long-term issuer and senior unsecured ratings at A2. The senior unsecured MTN programme rating has also been affirmed at (P)A2. The outlook remains stable. The affirmation of Lithuania's A2 ratings is supported by the count...
Moody's Ratings ("Moody's") has today changed the outlook on the Government of Albania to positive from stable and has affirmed the long-term foreign and local currency issuer ratings at B1. Concurrently, Moody's has also affirmed the foreign currency senior unsecured debt ratings at B1. Moody's d...
Moody's Ratings (Moody's) has upgraded the ratings on the following notes issued by Stratus CLO 2021-1, Ltd.: U.S.$60,000,000 Class B Senior Secured Floating Rate Notes due 2029, Upgraded to Aaa (sf); previously on December 29, 2021 Assigned Aa1 (sf) U.S.$25,000,000 Class C Mezzanine Secured Def...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NOVATO, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 44,965 restricted stock units of the company’s common stock to 14 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan...
Gulf Resources Announces Receipt of Nasdaq Non-Compliance Notice SHOUGUANG, China, April 19, 2024 (GLOBE NEWSWIRE) -- Gulf Resources, Inc. (NASDAQ: GURE) (“Gulf Resources” or the “Company”), a leading manufacturer of bromine, crude salt and specialty chemical products in China, today announced that it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that due to the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “2023 Form 10-K”), with...
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report CHASKA, Minn., April 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that, on April 15, 2024, the Company received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the fiscal quarter ended February 25, 2024 (the “Q3 Form 10-Q”) and its continued delay in filing its Quarterly Rep...
Arhaus Announces Showroom Opening in Greenwich, Connecticut The home brand unveils a 5,300 square-foot destination for heirloom quality furnishings BOSTON HEIGHTS, Ohio, April 19, 2024 (GLOBE NEWSWIRE) -- , a leader in artisan-crafted furniture and home décor, announces the opening of its new 5,300 square-foot showroom in Greenwich, Connecticut, located near the top of Greenwich Avenue in the city’s downtown shopping district. This marks the brand’s third showroom in Connecticut, with other locations in Farmington and Norwalk. The new Greenwich showroom is an inspiring destination ...
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it has begun wind-down activities in its ASCEND-NASH Trial, while continuing to explore strategic alternatives, as previously announced in December 2023. ASCEND-NASH is a Phase 2b, randomized, multi-cen...
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced its intention to voluntarily delist from the Nasdaq Global Market (“Nasdaq”) and to deregister its Class A common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and suspend its reporting obligations under Section 1...
Correction to Company announcement – No. 23 / 2024 Correction to Company announcement – No. 23 / 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has a correction to company announcement No. 23 /2024, April 19, 2024 - regarding transactions in Zealand’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons it was reported that mem...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.